Skip to Main Content

Guenther Koehne, MD, PhD

Professor and Chair of the Department of Translational Medicine, HWCOM; Deputy Director and Chief of Blood & Marrow Transplantation and Hematologic Oncology of the Miami Cancer Institute (MCI) at Baptist Health of South Florida

Office: AHC2 685

Phone: 786-527-8338


Areas of Interest/Focus: Treating patients with hematologic malignancies

Guenther Koehne, MD, PhD, is Professor and Chair of the Department of Translational Medicine comprising of three Divisions: Internal Medicine, Neurosciences, and Medical & Population Health Sciences Research at HWCOM. 

Dr. Koehne, a world-renowned medical oncologist, medical educator, and researcher, is the Deputy Director and Chief of Blood & Marrow Transplantation and Hematologic Oncology of the Miami Cancer Institute (MCI) at Baptist Health of South Florida.

Prior to joining MCI, Dr. Koehne was Associate Attending Physician of the Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine at Memorial Hospital in New York, and also as an Associate Professor of Medicine at Weill Medical College of Cornell University and Associate Member at Memorial Sloan-Kettering Cancer Center.


 Ph.D., Medicine, Medical University of Hamburg, Germany

 M.D., Medicine, Medical University of Hamburg, Germany

Selected Publications:

  1. Koehne G. Targeting WT1 in hematologic malignancies? 2017 Nov 2;130(18):1959-1960. doi: 10.1182/blood-2017-09-805358. PMID: 29097369
  2. Scordo M, Shah GL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, Carlow DC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, Perales MA, Giralt SA, Shaffer BC. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017 Sep 1. pii: S1083-8791(17)30688-2. doi: 10.1016/j.bbmt.2017.08.033. PMID: 28870777.
  3. Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM. Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. PMID: 28017734
  4. Hobbs GS, Kaur N, Hilden P, Ponce D, Cho C, Castro-Malaspina HR, Giralt S, Goldberg JD, Jakubowski AA, Papadopoulos EB, Sauter C, Koehne G, Yahalom J, Delvin S, Barker JN, Perales MA. A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 Mar 14. doi: 10.1038/bmt.2016.36. PMID: 26974271
  5. Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G and O’Reilly RJ. Immunotherapy with Donor T-cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent CMV Infection or Viremia. Biol Blood Marrow Transplant. 2015 May 29: S1083-8791(15)00372-9.
  6. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G, O’Reilly RJ. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood, Vol 116, No 23, 5045-5049, 2010, PMID 20826724
  7. O’Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-specific T cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res., 2007, Vol 38, 237-50, PMID 17917029.
  8. Trivedi D, Williams RY, O’Reilly RJ and Koehne G. Generation of Cytomegalovirus (CMV)-specific T lymphocytes using protein-spanning pools of pp65-derived over-lapping pentadecapeptides for adoptive immunotherapy. Blood, Vol 105, No 7, 2793 – 2801, 2005, PMID 15514011.
  9. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Balatoni J, Finn R, May C, Feldstein J, Riviere I, Blasberg R, Heller G, Sadelain M, O’Reilly RJ, Larson SM and Gelovani-Tjuvajev JG. Serial in vivo imaging of the targeted migration and persistence of human HSV-TK transduced antigen-specific T lymphocytes. Nature Biotechnology, Vol 21, 405 – 413, 2003, PMID 12652311.
  10. Koehne G, Smith KM, Ferguson TL, Williams RY, Heller G, Pamer EG, Dupont B and O’Reilly RJ. Quantitation, selection and functional characterization of EBV-specific and alloreactive T cells detected by intracellular interferon-g production and growth of cytotoxic precursors. Blood, Vol 99, No 5, 1730 – 1740, 2002, PMID 11861290.
  11. Koehne G, Gallardo HF, Sadelain M and O’Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood, Vol 96, 109-117, 2000, PMID 10891438.

Active Grants:

Guthart and Medina Fund, Pl: Guenther Koehne
01/01/2015 - 31/12/2020, active
Targeting WT1 on malignant plasma cells by heteroclitic peptide immunization

Research Areas

Dr. Koehne’s clinical focus is treating patients with hematologic malignancies. He is an expert in allogeneic (donor-derived) hematopoietic stem cell transplantation for patients with leukemia, lymphoma, myelodysplastic syndrome, and multiple myeloma.

Dr. Koehne is the principle investigator and leader of clinical trials to study the effectiveness of T cell-depleted transplants from related and unrelated donors in patients with high-risk and relapsed multiple myeloma. His research has focused on ways to reduce rates and to treat viral complications and disease recurrence following allogeneic stem cell transplantations.

Dr. Koehne is regarded in the medical community as a pioneer in developing specific donor-derived immune cells (T lymphocytes) to treat both the viral complications of transplantation and disease relapse following transplantation. This treatment approach has been termed “adoptive immunotherapy” and is being administered in several active clinical trials.